HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create cutting-edge cancer therapies, today announced that the Compensation Committee of the Board of Directors of the company granted fourteen new employees options to purchase an aggregate of 34,500 common shares of the Company at an exercise price per share of $28.78, which was the closing price on July 8, 2022, and units shares to acquire a total of 17,250 common shares of the Company. The equity awards were granted pursuant to the Company’s 2020 Incentive Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “Incentive Exception” under Rule 303A.08 of the NYSE Listed Companies Handbook.
About Arcus Biosciences
Arcus Biosciences is a global clinical-stage biopharmaceutical company developing differentiated molecules and combination drugs for people with cancer. In partnership with industry partners, patients, and physicians around the world, Arcus is accelerating the development of first-in-class or best-in-class drugs against well-characterized biology and pathways and investigating novel biology-based combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has accelerated the development of six investigational drugs into clinical studies, including novel combination approaches targeting TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and, most recently, HIF -2alpha. For more information on Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com or follow us on Twitter.
Source: Arcus Biosciences